KR101752487B1 - Composition for Treatment of Pancreatic Cancer and Functional Food Comprising Extract of Olibanum - Google Patents
Composition for Treatment of Pancreatic Cancer and Functional Food Comprising Extract of Olibanum Download PDFInfo
- Publication number
- KR101752487B1 KR101752487B1 KR1020110040577A KR20110040577A KR101752487B1 KR 101752487 B1 KR101752487 B1 KR 101752487B1 KR 1020110040577 A KR1020110040577 A KR 1020110040577A KR 20110040577 A KR20110040577 A KR 20110040577A KR 101752487 B1 KR101752487 B1 KR 101752487B1
- Authority
- KR
- South Korea
- Prior art keywords
- pancreatic cancer
- extract
- composition
- present
- oriental
- Prior art date
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 85
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 85
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 84
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 238000011282 treatment Methods 0.000 title claims abstract description 24
- 239000004863 Frankincense Substances 0.000 title claims description 14
- 241000717739 Boswellia sacra Species 0.000 title claims description 8
- 235000013376 functional food Nutrition 0.000 title abstract description 14
- 239000000284 extract Substances 0.000 title description 57
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 13
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 239000003085 diluting agent Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 7
- 230000006907 apoptotic process Effects 0.000 abstract description 4
- 239000000654 additive Substances 0.000 abstract description 3
- 230000000996 additive effect Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 239000003814 drug Substances 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 239000000843 powder Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 240000007551 Boswellia serrata Species 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 235000003717 Boswellia sacra Nutrition 0.000 description 6
- 235000012035 Boswellia serrata Nutrition 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 244000299461 Theobroma cacao Species 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000000582 semen Anatomy 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 240000007817 Olea europaea Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 101710113436 GTPase KRas Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000002725 Olea europaea Nutrition 0.000 description 3
- 244000184734 Pyrus japonica Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
- 210000000277 pancreatic duct Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 1
- 239000010268 Acori graminei Rhizoma Substances 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 241000208229 Burseraceae Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000594394 Hedyotis Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000835893 Homo sapiens Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000008663 Lycii Radicis Cortex Substances 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 239000009444 Nelumbinis Semen Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000722281 Saururus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 241000157352 Uncaria Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 239000012996 alamarblue reagent Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 206010006514 bruxism Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012325 curative resection Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000012336 endoscopic ultrasonography Methods 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- -1 ethyl oleate Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000001726 jatropha manihot extract Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000006259 organic additive Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- YXJHJCDOUFKMBG-BMZHGHOISA-M riboflavin sodium Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)[N-]C2=O YXJHJCDOUFKMBG-BMZHGHOISA-M 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 229940106668 yucca extract Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
본 발명은 유향 추출물의 신규한 용도에 관한 것에 관한 것으로서, 보다 상세하게는 유향 에탄올 추출물을 유효성분으로 함유하는 췌장암 예방 및 치료용 조성물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 유향 에탄올 추출물을 유효성분으로 함유하는 췌장암 예방용 기능성 식품에 관한 것이다. 본 발명에 따른 췌장암 치료용 조성물 및 기능성 식품은 췌장암 세포의 성장을 억제하고 세포사멸을 유도하는 효과가 있어 췌장암 치료 및 예방에 효과적으로 사용할 수 있다.
More particularly, the present invention relates to a composition for prevention and treatment of pancreatic cancer, which contains a crude ethanol extract as an active ingredient, and a flavored ethanol extract comprising a food acceptable food supplementary additive And a functional food for the prevention of pancreatic cancer. The composition and the functional food for treating pancreatic cancer according to the present invention have an effect of inhibiting the growth of pancreatic cancer cells and inducing apoptosis, and thus can be effectively used for the treatment and prevention of pancreatic cancer.
Description
본 발명은 유향 추출물의 신규한 용도에 관한 것이다. 구체적으로, 본 발명은 췌장암에 대해 탁월한 예방 또는 치료 효능을 나타내는 유향 추출물을 유효성분으로 함유하는 치료용 조성물 및 기능성 식품에 관한 것이다.
The present invention relates to a novel use of oriental extract. Specifically, the present invention relates to a therapeutic composition and a functional food containing an oriental extract having an excellent prophylactic or therapeutic efficacy against pancreatic cancer as an active ingredient.
현대인의 주요 질환 중에서, 암의 치료방법과 진단방법에 관한 연구는 발병빈도가 높은 폐암, 간암, 위암 등을 중심으로 비교적 활발히 진행되고 있다. 그러나, 발병빈도가 낮은 식도암, 대장암, 췌장암 등에 대한 연구는 상대적으로 저조한 실정이다.Among the major diseases of modern people, studies on the methods of treatment and diagnosis of cancer are progressing relatively actively, focusing on lung cancer, liver cancer, stomach cancer which have high incidence. However, studies on esophageal cancer, colorectal cancer, and pancreatic cancer which have low incidence are relatively low.
췌장은 인체에서 글루코오스를 에너지로 전환하는 것을 돕는 인슐린 및 인체에서 음식 소화를 돕는 효소를 생산한다. 췌장암은 췌장의 악성 성장으로서, 주로 췌장관의 세포에서 발생한다. 상기 질병은 아홉 번째로 가장 흔한 암 형태이지만, 남자와 여자에게 각각 네 번째 및 다섯 번째로 암 사망의 주된 원인이 된다. 췌장암은 3% 미만이 5년 생존율을 나타내어 대부분이 항상 치명적이다. 췌장암 중 췌장관에서 발생하는 췌장관 선암(腺癌)(pancreatic ductal adenocarcinoma)이 90% 이상을 차지하고 있어 일반적으로 췌장암이라고 하면 췌장관 선암을 말하는 것이다. 췌장관 선암은 췌장 선암, 췌관 선암 또는 췌장 선관암이라 불리기도 한다.The pancreas produces insulin that helps convert glucose into energy in the body and enzymes that help digest food in the body. Pancreatic cancer is a malignant growth of the pancreas, mainly occurring in cells of the pancreatic duct. The disease is the ninth most common form of cancer, but it is the fourth and fifth most common cause of cancer deaths for men and women, respectively. Pancreatic cancer has a 5-year survival rate of less than 3%, and most are always fatal. Among pancreatic cancer, pancreatic ductal adenocarcinoma (pancreatic ductal adenocarcinoma) in the pancreatic duct accounts for more than 90%. Generally, pancreatic cancer refers to pancreatic ductal adenocarcinoma. Pancreatic duct adenocarcinoma is also called pancreatic adenocarcinoma, pancreatic adenocarcinoma or pancreatic ductal cancer.
많은 다른 악성 질병과 같이 췌장암은 획득 돌연변이(acquired mutation)의 축적으로 발생한다. 원암유전자(protooncogenes)의 활성화, 종양 억제유전자(tumor suppressor genes)의 불활성화, 및 유지 유전자(maintenance genes)의 기형을 포함한 다중 유전적 및 후생유전적 변화가 췌장암의 발생, 지속된 성장, 및 전이와 관련이 있다. 이와 같은 유전자 내의 축적된 돌연변이가 "PanINs"(췌장 상피내 종양형성, Pancreatic Intraepithelial Neoplsia) 단계 동안 예상가능한 시간 안에 발생하는 것으로 알려져 있다(Hruban et al. (2000) Clin Cancer Res 6:2969-2972; Kern et al. (2002) Cancer Biol Therapy 1:607-613; Li et al. (2004) Lancet 363:1049-1057). K-ras의 돌연변이는 PanIN-1의 절반쯤에서 발생한다. PanIN-2 단계는 K-ras 돌연변이 속도의 부가의 변화 및 증가, 및 다수의 p16 기형의 외양으로 표시되며, p53 돌연변이의 존재를 나타낼 수 있는 p53 단백질 패밀리발현은 더 진보된 PanINs에서 때때로 나타난다. 종양 억제 유전자, TP53, DPC4 및 BRCA2의 손실은 췌장 종양형성, PanIN-3의 발생 후기에 생기는 것으로 보인다. 구체적으로, 췌장관 선암의 85% 이상이 췌장암 발생에서 활성화시킨 K-ras 유전자 점돌연변이(point mutation)를 가지고 있다(Li et al. (2004) Lancet 363:1049-1057; Xiong (2004) Cancer Chem Pharm 54:S69-77). K-ras 돌연변이는 세포 증식을 유도하여 이 유전자에 점돌연변이를 포함하는 세포상에 형질전환 성질을 부여하도록 하는 세포내 신호 경로(intracellular signaling pathway)인 Ras-Raf-MEK-ERK의 구성성분 활성화를 야기시킨다. 라스(ras) 돌연변이는 종양 단계 또는 예후에 연관되지 않으며, K-ras 발암유전자가 발암의 개시에 관련될 수 있으나 인간 췌장암의 악성일 가능성 또는 촉진에 연관되지는 않는 것을 가리킨다. 라스(ras) 패밀리의 주요한 다운스트림 타겟(downstream target) 중의 하나는 포스포이노시톨 3 키나제(phosphoinositol 3 kinase, PI3K)이다. PI3K의 활성화는 화학요법 또는 분자 약물표적화 약제에 의하여 유도된 세포사멸(apotosis)에 대한 췌장암 내성에 관련된다. Like many other malignant diseases, pancreatic cancer arises from the accumulation of acquired mutations. Multiple genetic and epigenetic changes, including activation of protooncogenes, inactivation of tumor suppressor genes, and malformations of maintenance genes have been linked to the development, persistent growth, and metastasis of pancreatic cancer . Accumulated mutations in these genes are known to occur within a predictable period of time during the "PanINs" (Pancreatic Intraepithelial Neoplasia) phase (Hruban et al. (2000) Clin Cancer Res 6: 2969-2972; Kern et al. (2002) Cancer Biol Therapy 1: 607-613; Li et al. (2004) Lancet 363: 1049-1057). The mutation of K-ras occurs at about half of the PanIN-1. The PanIN-2 stage is indicated by an additional change and an increase in the K-ras mutation rate, and a plurality of p16 malformations, and p53 protein family expression, which may indicate the presence of p53 mutations, is occasionally seen in more advanced PanINs. Loss of tumor suppressor genes, TP53, DPC4 and BRCA2, appears to occur later in the development of pancreatic tumor formation, PanIN-3. Specifically, over 85% of pancreatic ductal adenocarcinomas have a K-ras gene point mutation activated in the development of pancreatic cancer (Li et al. (2004) Lancet 363: 1049-1057; Xiong Pharm 54: S69-77). The K-ras mutation induces cell proliferation and activates the constitutive elements of Ras-Raf-MEK-ERK, an intracellular signaling pathway that allows this gene to be transfected with cells containing point mutations. . The ras mutation is not associated with the tumor stage or prognosis and indicates that the K-ras oncogene may be involved in the onset of carcinogenesis but is not associated with the possibility or promotion of malignancy of human pancreatic cancer. One of the major downstream targets of the ras family is phosphoinositol 3 kinase (PI3K). Activation of PI3K is associated with pancreatic cancer resistance to apoptosis induced by chemotherapy or molecular drug targeting agents.
췌장관 선암은 미국에서만 사망자가 매년 30,000명 이상에 달하는 가장 치명적인 인간 악성 종양 중의 하나이다. 진단시 이들 암은 국부적으로 진행되는 질환 또는 원격 전이의 존재로 인하여, 단지 10% 내지 15%만이 절제될 수 있는 상태로 발견된다. 최근에, 가장 일반적인 진행성 췌장암의 치료 전략은 인간 췌장암 세포의 세포 자멸을 유도하고 종양의 성장 및 진행을 억제할 수 있는 정맥 투여용 2'-디옥시시티딘 뉴글레오사이드 유사체인 겜시타빈(gemcitabine)에 의한 치료법이다. 그러나, 최고의 의학적 또는 외과적 치료에도 불구하고, 췌장관 선암 환자의 치료 결과는 참담하며, 하나의 집단으로서, 이 질환 환자의 정중(正中) 생존 기간은 21개월 이하이다. 따라서, 이 치명적 질병에 대처하기 위한 분명하고도 새롭고 효율적인 치료 전략이 요구되고 있다. 이와 같이, 췌장암은 선진국의 주요한 유향상의 이슈이며, 매우 불량한 예후를 가지고 있다(Faint et al. (2004) Datamonitor DMHC2045; Garcea et al. (2005) Pancreatology 5:514-529; Kern et al. (2002) Cancer Biol Therapy 1:607-613; Laheru and Jaffee (2005) Nature Rev Cancer 5:59-467; Li et al.(2004) Lancet 363:1049-1057). 과도한 외과 및 의학적 치료에도 불구하고, 평균기대수명이 국부 질환 환자의 경우에는 약 15-18개월이고, 전이성 질환 환자의 경우에는 3-6개월이다. 거의 100%의 췌장암 환자들은 전이를 경험하며, 그들의 제한되지 않은 성장으로 신진대사를 약화시키는 작용으로 인하여 죽음에 이르며, 절제수술을 하지 않은 환자들이 총 5년을 생존할 가능성은 5% 미만에 불과하다. 또한, 특이적이지 않은 초기 증상으로 인하여 초기 진단이 어렵다는 문제점이 있다. 현재, 췌장암의 초기 감지법은 아직 개발 중에 있어 상용화되어 있지 않으며, 종래의 암치료법으로는 예후 또는 질병 결과에 거의 영향을 미치지 않는다. 췌장암의 불량한 예후는 늦은 표시, 공격적인 국부 침입, 초기 전이 및 화학요법에 대한 불충분한 반응으로 인한 것이다.
Pancreatic duct adenocarcinoma is one of the most deadly human malignant tumors in the United States, with more than 30,000 deaths annually. At the time of diagnosis, these cancers are found to be only able to be resected, with only 10% to 15% being due to the presence of locally advanced disease or distant metastasis. Recently, the most common treatment strategy for advanced pancreatic cancer is gemcitabine, an intravenous 2'-deoxycytidine neuroleoside analogue that can induce apoptosis of human pancreatic cancer cells and inhibit tumor growth and progression, Lt; / RTI > However, despite the best medical or surgical treatment, the outcome of patients with pancreatic ductal adenocarcinoma is dismal and as a group, the median survival of patients with this disease is less than 21 months. Therefore, clear, new and effective treatment strategies are needed to combat this fatal disease. Pancreatic cancer is a major milestone in advanced countries and has a very poor prognosis (Faint et al. (2004) Datamonitor DMHC2045; Garcea et al. (2005) Pancreatology 5: 514-529; Kern et al. 2002) Cancer Biol Therapy 1: 607-613; Laheru and Jaffee (2005) Nature Rev Cancer 5: 59-467; Li et al. (2004) Lancet 363: 1049-1057). Despite excessive surgical and medical treatment, the average life expectancy is approximately 15-18 months for patients with local disease and 3-6 months for patients with metastatic disease. Nearly 100% of patients with pancreatic cancer experience metastases and die due to their ability to weaken metabolism by their unrestrained growth, and the likelihood of survival for a total of five years without resection is only less than 5% Do. Also, there is a problem that early diagnosis is difficult due to initial symptoms that are not specific. Currently, early detection of pancreatic cancer is still under development and not commercially available, and conventional cancer therapy has little effect on prognosis or disease outcome. Poor prognosis of pancreatic cancer is due to late signs, aggressive local invasion, early metastasis and insufficient response to chemotherapy.
췌장암의 가장 흔한 증상은 황달, 복통 및 체중 감소 등을 들 수 있으며, 다른 출현 인자들과 함께 실질적으로 특별한 것은 아니다. 따라서, 종양 성장의 초기 단계에서 췌장암을 진단하는 것이 대개 어렵고, 상당한 의혹 및 광범위한 진단용 정밀검사, 종종 시험적 수술(exploratory surgery)을 포함하는 상황을 필요로 한다. 내시경초음파검사(endoscopic ultrasonography) 및 컴퓨터단층촬영(computed tomography, CT)은 현재 췌장암 진단을 위하여 이용할 수 있는 비침입성 방법 중 가장 좋은 것이다. 그러나, 병소의 췌장염으로부터 췌장암의 분화뿐만 아니라 작은 종양의 확실한 검출은 힘들다. 공교롭게도, 환자의 대다수가 현재 종양이 이미 주변 기관을 침입하여 막낭의 외부로 연장되고 및/또는 광범위하게 전이된 말기 단계에서 진단되고 있다(Gold et al., Crit. Rev. Oncology/Hematology, 39 :147-54(2001)). 상기 질병은 뒤늦은 검출이 일반적이고, '조기' 췌장암 진단은 임상적 상황(clinical setting)에서 드문 일이다.The most common symptoms of pancreatic cancer are jaundice, abdominal pain and weight loss, and are not really special with other adverse factors. Thus, in the early stages of tumor growth, diagnosing pancreatic cancer is usually difficult, and requires considerable suspicion and extensive diagnostic overcrowding, often involving exploratory surgery. Endoscopic ultrasonography and computed tomography (CT) are currently the best noninvasive methods available for the diagnosis of pancreatic cancer. However, definite detection of small tumors as well as differentiation of pancreatic cancer from lesion pancreatitis is difficult. Unfortunately, the majority of patients are now diagnosed at the terminal stage where the tumor has already invaded the surrounding organs and extended outside the caecum and / or at the extensively metastasized stage (Gold et al., Crit. Rev. Oncology / Hematology, 39: 147-54 (2001)). The disease is delayed detection is common, and 'early' pancreatic cancer diagnosis is rare in the clinical setting.
현재 췌장암을 위해 사용할 수 있는 치료 방법은 병을 치유 또는 실질적으로 개선된 생존 시간에 도달하지 못하고 있다. 수술 절제만이 생존의 기회를 제공하는 유일한 방법이다. 그러나, 종양 적하(tumor burden)로 인해 환자의 10-25% 만이 '근치적 절제(curative resection)'를 위한 대상이 된다. 절제 치료를 경험하는 이들 환자들에게서, 5년의 생존율은 평균적으로 대략 10% 정도로 아직 미흡하다.
Current treatments that can be used for pancreatic cancer do not reach the healing or substantially improved survival time of the disease. Surgical resection is the only way to provide an opportunity for survival. However, due to tumor burden, only 10-25% of patients are targeted for 'curative resection'. In these patients who experience resection, the 5-year survival rate is still on the order of 10% on average.
한편, 유향(Olibanum)은 감람과에 속하는 유향나무의 진을 말린 것으로 나무줄기에 상처를 내어 흘러나오는 우유같은 액즙을 공기 중에 두면 굳어지는데 이를 긁어 내어 잡질을 없애고 말린다. 맛은 맵고 약성은 온화하다. 혈액순환이 잘되게 하고, 진통, 경련을 멈추게 하며 타박상 부스럼 월경통 월경불순 산후복통 등에 쓰인다. 외용약으로 쓸 때는 가루로 만들어 뿌리거나 기초제에 개어서 붙인다. 유향은 감람나무과에 속하는 활혈약으로 맛은 시고 쓰고, 성질은 따뜻하며 귀경(歸經)은 심(心), 간(肝), 폐(肺)경이다. 유향의 효능은 활혈지통(活血止痛)으로 임상에서는 어혈로 인한 동통 등에 응용되고 있다.On the other hand, Olibanum is dried olive branch of olive tree belonging to olive tree, and it is hardened by putting milk liquid such as milk which comes out from the tree trunk out and scraping it, and removing it and drying it. The taste is spicy and the mildness is mild. It helps blood circulation, analgesic and cramps to stop, bruxism, dysmenorrhea, menstrual irregularity, and abdominal pain. When used as an external medicine, it is made into powder or sprinkled or put on a foundation. The frankincense is a bacterium belonging to the olive tree family, and it tastes and writes. The nature is warm, and the vinegar is the heart, the liver, and the lungs. The efficacy of frankincense (动血 止痛) is the clinical application of pain due to hemorrhoids are applied.
본 발명에서 사용되는 유향은 유향나무(Boswellia Carterii Birdwood) 및 동속근연식물(감람과 Burseraceae)의 간피에 상처를 내어 얻은 수지로 길이 5-30 ㎜의 구형 또는 고르지 않은 알맹이로서 바깥면은 엷은 황색-황백색 또는 적색, 회색 등 여러가지 색을 띠며 겉에 백색의 고운가루가 묻어있고 반투명이며, 방향성의 냄새가 있고 맛은 조금 쓰며 점액성이며, 약리작용으로 진통작용 소염작용, 항결핵작용이 있는 것으로 알려져 있다. 유향의 주요성분으로는 보스웨릭산(Boswellic acid), 오리바노레세네(Olibanoresene), 보스웨리디닉산(Boswelidinic acid), 피네네(Pinene)를 포함한다. 또한, 유향(Olihanum)은 유향수의 수지로서 강력한 진통작용과 신경안정작용, 월경통, 종양, 피부염 등에 효과가 우수하다.The fragrance used in the present invention is a resin obtained by scratching the cortex of Boswellia Carterii Birdwood and related plants (olive and Burseraceae), and is spherical or uneven with a length of 5-30 mm. Outer surface is pale yellow-yellowish white It is known that it has various kinds of colors such as red, gray, white fine powder on its surface, translucent, aromatic smell, little taste, mucinous, pharmacological action, analgesic action, antituberculous action . The main ingredients of the frankincense include Boswellic acid, Olibanoresene, Boswelidinic acid, Pinene. In addition, Olihanum is a resin of perfume, and it has excellent effects on strong analgesic action, nervous stability, dysmenorrhea, tumor, dermatitis.
그러나, 유향의 췌장암 관련 질환과 관련하여 상기 문헌 어디에도 개시되거나 공개된 바가 없다.
However, there are no disclosures or disclosures in this document anywhere in relation to oriental pancreatic cancer-related diseases.
이에, 본 발명자들은 유향에 대한 생약 연구를 하던 중, 유향 추출물이 췌장암 세포를 효과적으로 사멸시킬 수 있음을 확인함으로써 본 발명을 완성하였다.
Accordingly, the inventors of the present invention completed the present invention by confirming that the oriental extract can effectively kill pancreatic cancer cells while conducting herbal medicine for oriental medicine.
본 발명의 목적은 유향 추출물을 유효성분으로 함유하는 췌장암 치료용 조성물 및 기능성 식품을 제공하는 것이다.
It is an object of the present invention to provide a composition for treating pancreatic cancer and a functional food containing the oriental extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 유향(Olibanum) 에탄올 추출물을 유효성분으로 함유하는 췌장암 예방 및 치료용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for preventing and treating pancreatic cancer, which comprises an extract of Olibanum ethanol as an active ingredient.
또한, 본 발명은 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 유향(Olibanum) 에탄올 추출물을 유효성분으로 함유하는 췌장암 예방용 기능성 식품을 제공한다.
In addition, the present invention provides a functional food for the prevention of pancreatic cancer, which contains as an active ingredient an olibanum ethanol extract containing a food-acceptable food-aid additive.
이하, 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명은 유향(Olibanum) 에탄올 추출물을 유효성분으로 함유하는 췌장암 예방 및 치료용 조성물을 제공한다. 본 발명의 조성물은 활성성분으로서 유향 추출물을 포함하며, 추가적으로 약제학적으로 허용가능한 담체 또는 희석제를 포함할 수 있다.The present invention provides a composition for preventing and treating pancreatic cancer, which comprises an extract of Olibanum ethanol as an active ingredient. The composition of the present invention comprises oriental extract as an active ingredient and may further comprise a pharmaceutically acceptable carrier or diluent.
본 발명의 췌장암 예방 및 치료용 조성물에 있어서, 상기 에탄올 추출물은 50℃에서 24시간 동안 추출되는 것이 바람직하고, 이때 상기 에탄올 추출물은 45℃ 감압 조건에서 건조 및 농축되는 것이 보다 바람직하며, 상기 에탄올은 95%인 것이 가장 바람직하다.In the composition for preventing and treating pancreatic cancer according to the present invention, it is preferable that the ethanol extract is extracted at 50 ° C for 24 hours, and the ethanol extract is more preferably dried and concentrated under reduced pressure at 45 ° C, Most preferably 95%.
또한, 본 발명의 췌장암 예방 및 치료용 조성물에 있어서, 상기 췌장암은 췌장관 선암(pancreatic ductal adenocarcinoma)인 것이 바람직하다.In addition, in the composition for preventing and treating pancreatic cancer of the present invention, the pancreatic cancer is preferably pancreatic ductal adenocarcinoma.
본 발명의 유향 추출물은 유향의 어느 부위에서도 가능하다. 그리고 추출용액은 물 또는 유기용매로 추출하여 얻을 수 있는데, 유기용매로는 저급 알콜, 아세톤, 클로로포름, 메틸렌클로라이드, 에테르, 에틸아세테이트, 헥산 등을 예시할 수 있다. 저급알콜로는 메탄올, 에탄올, 프로판올 및 부탄올을 예시할 수 있으며, 에탄올이 가장 바람직하다.The oriental extract of the present invention can be used at any site of oriental. The extraction solution can be obtained by extraction with water or an organic solvent. Examples of the organic solvent include lower alcohol, acetone, chloroform, methylene chloride, ether, ethyl acetate, hexane and the like. As the lower alcohol, methanol, ethanol, propanol and butanol can be mentioned, and ethanol is most preferable.
구체적으로, 유향 건조물 또는 분말에 1 내지 5 배, 바람직하게는 3배의 95% 에탄올을 첨가하고 20 내지 100℃, 바람직하게는 40 내지 60℃의 온도에서 10 내지 100시간, 바람직하게는 15 내지 40시간, 더욱 바람직하게는 24시간 동안 추출한 후 여과하여 유향의 에탄올 추출물을 제조할 수 있다. 바람직하게는 상기 추출액을 여과하여 얻어진 여액을 감압농축하여 제조할 수 있다. 상기 추출방법들에서 추출 공정은 필요에 따라 2회 이상 반복하여 실시할 수 있으며, 여과 후 얻어진 추출물을 동결 건조 또는 감압건조시켜 분말 형태로 만들 수도 있다.
Specifically, 95 to 90% ethanol is added to the dried product or powder at 1 to 5 times, preferably 3 times, at a temperature of 20 to 100 占 폚, preferably 40 to 60 占 폚 for 10 to 100 hours, For 40 hours, more preferably for 24 hours, and then filtered to prepare an ethanol extract of scent. Preferably, the extract is filtered, and the resulting filtrate is concentrated under reduced pressure. In the above extraction methods, the extraction process may be repeated twice or more as necessary, and the extract obtained after filtration may be lyophilized or dried under reduced pressure to a powder form.
상기 "약제학적으로 허용가능한 담체"는 신체의 한 기관 또는 부분으로부터 신체의 다른 기관 또는 부분으로 활성 성분을 수송하는 역할을 하는 액체 또는 고체 충진제, 희석제, 부형제 또는 용매와 같은 약제학적으로 허용되는 물질, 조성물 또는 운반체(vehicle)를 의미한다.The term "pharmaceutically acceptable carrier" is intended to encompass pharmaceutically acceptable substances, such as liquid or solid fillers, diluents, excipients or solvents, which serve to transport the active ingredient from one or more parts of the body to other organs or parts of the body , Composition or vehicle.
본 발명의 췌장암 치료용 조성물은 유효성분과 함께 추가로 약제학적으로 허용되는 1종 이상의 담체를 첨가하여 약제로 제조할 수 있다. 상기 담체로는 식염수, 완충 식염수, 물, 글리세롤 및 에탄올 등이 있으나 이에 한정되지 않으며, 당해 기술 분야에 알려진 적합한 제제(Remingtons's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA)를 모두 사용 가능하다.The composition for treating pancreatic cancer of the present invention may be prepared from a pharmaceutical agent by adding one or more pharmaceutically acceptable carriers together with the active ingredient. Such carriers include, but are not limited to, saline, buffered saline, water, glycerol, and ethanol, and any suitable formulation known in the art (Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA) .
본 발명의 유향 추출물을 약제화하기 위한 제제는 임상 투여시에 경구로 투여가 가능하며 일반적인 의약품 제제의 형태로 사용될 수 있으며, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드, 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제 감미제, 방향제, 보존제 등이 포함될 수 있다.The formulation for weakening the fragrant extract of the present invention can be administered orally at the time of clinical administration and can be used in the form of a general pharmaceutical preparation. In the case of formulation, a filler, an extender, a binder, a wetting agent, A surfactant, or the like. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like. Examples of liquid formulations for oral use include suspensions, solutions, emulsions and syrups. Common diluents such as water, In addition to liquids and paraffins, various excipients such as wetting agent sweetening agents, perfumes, preservatives and the like may be included.
또한, 본 발명의 조성물에 추가될 수 있는 생약재는 약학적으로 허용되는 임의의 생약재일 수 있으며, 예를 들면, 고본(Angelicae tenuissimae Radix), 천마(Gastrodiae Rhizoma), 시호(Bapleuri Radix), 당귀(Angelicae gigantis Radix), 도인(Persicae Semen), 계지(Cinnamomi Ramulus), 대황(Rhei Rhizoma), 감초(Glycyrrhizae Radix), 천궁(Cnidii Rhizoma), 진피(Aurantii nobilis Pericarpium), 택사(Alismatis Rhizoma), 황련(Coptidis Rhizoma), 황금(Scutellariae Radix), 복령(Hoelen), 작약(Paeoniae Radix), 백출(Atractylodis Rhizoma alba), 황백(Phellodendri Cortex), 치자(Gardeniae Fructus), 반하(Pinelliae Tuber), 조구등(Uncaria Ramuluset Uncus), 지실(Ponciri Fructus), 인삼(Gingseng), 맥문동(Liriopis Tuber), 원지(Polygalae Radix), 석창포(Acori graminei Rhizoma), 창출(Atractylodis Rhizoma alba), 감국(Chrysanthemi Flos), 방풍(Ledebouriellae Radix), 생강(Olibanum crudus), 망초(Natrii sulfas), 대조(Zizyphi Fructus), 단삼(Salviae Radix), 목단피(Mautan Radicis Cortex), 지황(Rehmanniae Radix), 박하(Menthae Herba), 산약(Dioscoreae Rhizoma), 저령(Polyporus), 하수오(Polygonimultiflori Radix), 구자(Allii tuberosi Semen), 결명자(Cassiae Semen), 구기자(Lycii Fructus), 독활(Araliae cordatae Radix), 두충(Eucommiae Cortex), 백화사설초(Hedyotis Herba), 삼백초(Saururus Herba), 인진(Artemisiaecapillaris Herba), 지모(Anemarrhenae Rhizoma), 홍화(Carthami Flos), 황기(Astragali Radix), 석송자(Lycopodium), 은행잎(Ginkgonis Folium), 황정(Polygonati Rhizoma), 연자육(Nelumbinis Semen), 용골(Fossilia ossis Mastodi), 지골피(Lycii radicis Cortex), 우슬(Achyranthis Radix), 숙지황(Rehmanniae Radix preparata), 흑임자(Perillae Semen), 백자인(Thujae Semen), 맥아(Hordei Fructus germinatus), 토사자(Cuscutae Semen), 파극천(Morindae Radix), 해송(Pini koraiensis Radix) 등을 단독으로 또는 배합하여 사용할 수 있다.
In addition, the herbal medicine which may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelicae tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, (Rhizoma), Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhei Rhizoma, Glycyrrhizae Radix, Cnidii Rhizoma, Aurantii nobilis Pericarpium, Alismatis Rhizoma, Coptidis Rhizoma, Scutellariae Radix, Hoelen, Paeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Uncaria Ramuluset, Uncus, Ponciri Fructus, Ginseng, Liriopis Tuber, Polygalae Radix, Acori graminei Rhizoma, Atractylodis Rhizoma alba, Chrysanthemi Flos, Ledebouriellae Radix, ), Ginger (Olibanum crudus, Natrii sulfas), control (Zizyphi Fruct Mintan Radicis Cortex, Rehmanniae Radix, Menthae Herba, Dioscoreae Rhizoma, Polyporus, Polygonimultiflori Radix, Allii tuberosi Semen, Salviae Radix, ), Cassiae Semen, Lycii Fructus, Araliae cordatae Radix, Eucommiae Cortex, Hedyotis Herba, Saururus Herba, Artemisiaecapillaris Herba, Anemarrhenae Rhizoma Carthami Flos, Astragali Radix, Lycopodium, Ginkgonis Folium, Polygonati Rhizoma, Nelumbinis Semen, Fossilia ossis Mastodi, Lycii radicis Cortex, , Achyranthis Radix, Rehmanniae Radix preparata, Perillae Semen, Thujae Semen, Hordei Fructus germinatus, Cuscutae Semen, Morindae Radix, Pini koraiensis Radix, ) May be used alone or in combination.
본 발명의 조성물은 실제 임상 투여시에 비경구의 여러 가지 제형으로 투여될 수 있는데, 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드, 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제 감미제, 방향제, 보존제 등이 포함될 수 있다. 구체적으로, 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. 또한 치료제의 효능 증진을 위해 칼슘이나 비타민 D3를 첨가할 수 있다. 이러한 조성물은 단위-용량(1회분) 또는 다중-용량(수 회분) 용기, 예를 들면, 밀봉된 앰풀 및 바이알에 제시될 수 있고, 사용 직전에 멸균성 액상 담체, 예를 들면, 주사용 수의 부가 만을 요구하는 동결-건조 조건 하에 저장할 수 있다. 즉석의 주사 용제 및 현탁제는 멸균성 산제, 과립제 및 정제로부터 제조할 수 있다.The composition of the present invention can be administered in various forms of parenteral administration at the time of actual clinical administration. Solid formulations include tablets, pills, powders, granules, capsules and the like. Examples of the liquid formulations include suspensions, , Syrups, and the like. Various excipients such as wetting agent sweeteners, fragrances, preservatives, etc. may be included in addition to simple diluents commonly used in water, liquids and paraffins. Specifically, formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like. Calcium or vitamin D 3 may also be added to enhance the efficacy of the therapeutic agent. Such compositions may be presented in unit-dose (one-time) or multi-dose (several-dose) containers, such as sealed ampoules and vials, and may be presented in a sterile liquid carrier, Lt; RTI ID = 0.0 > freeze-drying < / RTI > Immediate injectable solutions and suspensions may be prepared from sterile powders, granules and tablets.
본 발명의 제제는 대상의 연령, 성별, 상태, 체내에서 활성 성분의 흡수도, 불활성율 및 배설속도, 병용되는 약물에 따라 달리 적용될 수 있다. 본 발명은 또한 투약 단위의 제형들을 포함한다. 제형은 개별 투약 형태, 예를 들면 정제, 피복 정제, 캡슐제, 환제, 좌약 및 앰플제로 존재하고, 약제 중 유효 화합물의 함량은 개별 투약량의 분율 또는 배수에 해당한다. 투약 단위는, 예를 들면 개별 투여량의 1, 2, 3 또는 4배로, 또는 1/2, 1/3 또는 1/4배를 함유할 수 있다. 개별 투여량은 바람직하기로는 유효 화합물이 1회에 투여되는 양을 함유하며, 이는 통상 1일 투여량의 전부, 1/2, 1/3 또는 1/4배에 해당한다.
The formulations of the present invention may be applied differently depending on the age, sex, condition of the subject, the degree of absorption of the active ingredient in the body, the rate of inactivation and the rate of excretion, and the drugs used in combination. The present invention also includes formulations of dosage units. The formulations are presented in separate dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, and the content of active compound in the drug is a fraction or multiple of the individual dosage. Dosage units may contain, for example, 1, 2, 3 or 4 times, or 1/2, 1/3 or 1/4 times the individual doses. The individual doses preferably contain amounts in which the active compound is administered in a single dose, which usually corresponds to the full, half, one-third or one-fourth of the daily dose.
본 발명에서 용어, "추출물(extract)"은 천연물로부터 분리된 활성성분을 의미한다. 추출물은 물, 유기용매, 또는 이의 혼합용매를 이용하는 추출과정으로 획득할 수 있으며, 추출액, 이의 건조 분말 또는 이를 이용하여 제형화된 모든 형태를 포함한다.
As used herein, the term "extract " means an active ingredient isolated from a natural product. The extract can be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or all the forms formulated with it.
본 발명의 구체적인 실시에서, 유향의 에탄올 추출물은 Panc-1 췌장암 세포를 100 ㎍/㎖에서 96.3% 사멸시키고, IC50(half maximal inhibitory concentration)은 36.1 ㎍/㎖이었다. 상기 결과는 본 발명의 유향 추출물이 우수한 Panc-1 췌장암 세포의 사멸 활성을 가지며, 나아가 췌장암 치료 및 예방 활성을 가진다는 것을 입증하는 것이다.
In a specific embodiment of the present invention, the ethanol extract of oriental was killed 96.3% at 100 μg / ml of Panc-1 pancreatic cancer cells and the IC 50 (half maximal inhibitory concentration) was 36.1 μg / ml. The above results demonstrate that the oriental extract of the present invention has an excellent killing activity of Panc-1 pancreatic cancer cells and further has a pancreatic cancer treatment and prevention activity.
본 발명에서 용어, "예방"이란 조성물의 투여로 췌장암 발병을 억제 또는 지연시키는 모든 행위를 의미한다.As used herein, the term "prevention" means any action that inhibits or delays the onset of pancreatic cancer by administration of the composition.
본 발명에서 용어, "치료"란 조성물의 투여로 췌장암의 증세가 호전되거나 이롭게 변경하는 모든 행위를 의미한다.In the present invention, the term "treatment" means any action that improves or alters the symptoms of pancreatic cancer by administration of the composition.
본 발명에서 유향 추출물은 물, 유기 용매, 또는 이의 혼합 용매를 사용하여 추출하여 사용할 수 있다. 바람직하게는 유기 용매, 특히 에탄올을 사용하여 추출한다. 추출한 액은 바로 사용하거나 또는 농축 및/또는 건조하여 사용할 수 있다. 유기용매를 사용하여 추출하는 경우, 메탄올, 에탄올, 이소프로판올, 부탄올, 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N, N-디메틸포름아미드(DMF), 디메틸설폭사이드(DMSO), 1,3-부틸렌글리콜, 프로필렌글리콜 또는 이들의 혼합용매인 유기용매를 사용하며 생약의 유효 성분이 파괴되지 않거나 최소화된 조건에서 실온 또는 가온하여 추출할 수 있다. 추출하는 유기용매에 따라 약제의 유효성분의 추출정도와 손실정도가 차이가 날 수 있으므로, 알맞은 유기용매를 선택하여 사용하도록 한다. 추출 방법은 특별히 제한되지 않고, 예를 들어 냉침 추출, 초음파 추출, 환류 냉각 추출 등이 있다. 여과는 추출액으로부터 부유하는 고체 입자를 제거하는 과정으로, 면, 나일론 등을 이용하여 입자를 걸러내거나 한외여과, 냉동여과법, 원심분리법 등을 사용할 수 있으나 이에 제한되지 않는다.In the present invention, the oriental extract can be extracted by using water, an organic solvent, or a mixed solvent thereof. Preferably an organic solvent, especially ethanol. The extracted liquid can be used directly or by concentrating and / or drying. In the case of extraction using an organic solvent, an organic solvent such as methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF) (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof. The active ingredient of the herbal medicine may be extracted at room temperature or warmed under the condition that the active ingredient is not destroyed or minimized. Depending on the organic solvent to be extracted, the degree of extraction and the degree of loss of the active ingredient of the medicament may differ. Therefore, an appropriate organic solvent should be selected and used. The extraction method is not particularly limited, and examples thereof include cold extraction, ultrasonic extraction, and reflux cooling extraction. Filtration is a process of removing suspended solid particles from an extract, and may be performed by filtering particles using a cotton, nylon, or the like, or by ultrafiltration, freezing filtration, centrifugation, and the like.
추출액의 농축에는 감압농축, 역삼투압 농축 등의 방법이 사용될 수 있다. 농축 후 건조 단계는 동결건조, 진공건조, 열풍건조, 분무건조, 감압건조, 포말건조, 고주파건조, 적외선건조 등을 포함하나 이에 제한되지 않는다. 경우에 따라, 최종 건조된 추출물을 분쇄하는 공정을 추가할 수 있다.Concentration of the extract can be carried out by reduced-pressure concentration, reverse osmosis concentration, or the like. The post-concentration drying step includes, but is not limited to, freeze drying, vacuum drying, hot air drying, spray drying, vacuum drying, foam drying, high frequency drying, infrared drying and the like. In some cases, a step of pulverizing the final dried extract may be added.
또한, 상기 추출물은 추가의 분획 공정을 수행할 수 있다. 바람직하게는 상기 추출물을 증류수에 현탁시켜 비극성 유기 용매, 예를 들어, 헥산, 에테로, 디클로로메탄, 클로로포름, 에틸아세테이드 또는 이들의 혼합 용매로 비극성용매 가용층을 추출, 분리하여 수득하도록 하고, 이를 농축 및/또는 건조하여 사용할 수 있다.In addition, the extract may be subjected to an additional fractionation process. Preferably, the extract is suspended in distilled water, and the non-polar solvent soluble layer is extracted and separated by using a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof , Which can be used by concentration and / or drying.
본 발명에서, 용어 "약제학적으로 허용가능한 염"이란 약리학적 또는 생리학적으로 허용되는 무기산, 유기산 및 염기로부터 유도된 염을 의미한다. 적합산 산의 예로는 염산, 브롬산, 황산, 질산, 과염소산, 푸마르산, 말레산, 인산, 글리콜산, 락트산, 살리실산, 숙신산, 톨루엔-p-설폰산, 타르타르산, 아세트산, 시트르산, 메탄설폰산, 포름산, 벤조산, 말론산, 나프탈렌-2-설폰산, 벤젠설폰산 등을 포함할 수 있다. 적합한 염기로부터 유도된 염은 알칼리 금속, 예들 들어, 나트륨, 알칼리토금속, 예들 들어, 마그네슘, 암모늄 등을 포함할 수 있다.
In the present invention, the term "pharmaceutically acceptable salt" means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene- Formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like. Salts derived from suitable bases may include alkali metals, such as sodium, alkaline earth metals, such as magnesium, ammonium, and the like.
본 발명의 췌장암 질환 예방 및 치료용 약학조성물은 조성물 총 중량에 대하여 상기 추출물 또는 화합물을 0.1 내지 50 중량%로 포함한다. 또한, 상기 조성물은 약효를 증가시키지는 않으나 약재 조성물에 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가성분을 포함할 수 있다. 또한, 상기 조성물은 비타민 B1, B2, B6, C, E, 니아신, 카르니친, 베타인, 엽산 판토텐산, 비오틴, 아연, 철, 칼슘, 크롬, 마그네슘, 이들의 혼합물 등의 무기, 유기 첨가물들을 추가로 포함할 수 있다. 또한, 상기 조성물은 단독 사용하거나 기존 사용되어진 췌장암에 대한 치료 활성을 가지는 물질을 포함할 수 있다.
The pharmaceutical composition for the prevention and treatment of pancreatic cancer diseases according to the present invention comprises 0.1 to 50% by weight of the above extract or compound, based on the total weight of the composition. In addition, the composition does not increase the efficacy, but may contain additional ingredients that are commonly used in pharmaceutical compositions to improve odor, taste, visual appearance, and the like. In addition, the composition may further comprise inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folic acid pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, As shown in FIG. In addition, the composition may include a substance having therapeutic activity against pancreatic cancer alone or in a previously used form.
본 발명에서 용어, "환자"는 췌장암 및 이의 직, 간접적 원인에 의해 유발된 질환을 가지고, 본 발명의 조성물을 투여에 의하여 증상이 호전될 수 있는 인간과 말, 양, 돼지, 염소, 낙타, 영양, 개 등의 동물을 의미한다. 본 발명의 유향 추출물을 포함하는 조성물을 환자에게 투여함으로써, 상기에서 언급한 췌장암을 효과적으로 예방 및 치료할 수 있다. 본 발명의 조성물을 기존의 췌장암 치료제와 병행하여 투여할 수 있다.The term "patient" in the present invention refers to a disease caused by pancreatic cancer and its direct or indirect cause, and can be administered to humans, horses, sheep, pigs, goats, camels, Nutrition, and dogs. By administering to a patient a composition comprising the oriental extract of the present invention, the above-mentioned pancreatic cancer can be effectively prevented and treated. The composition of the present invention can be administered in parallel with the existing pancreatic cancer therapeutic agent.
본 발명에서 용어, "투여"는 어떠한 적절한 방법으로 환자에게 소정의 물질을 도입하는 것을 의미하며, 본 발명의 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여 경구 또는 비경구 투여될 수 있다. 또한, 조성물은 활성 물질이 표적 세포로 이동할 수 있는 임의의 장치에 의해 투여될 수 있다.The term "administering" in the present invention means introducing a predetermined substance into a patient in any appropriate manner, and the administration route of the composition of the present invention may be oral or parenteral ≪ / RTI > The composition may also be administered by any device capable of transferring the active agent to the target cell.
본 발명의 조성물은 약제학적으로 유효한 양으로 투여한다. 본 발명에서 용어, "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 환자의 성병, 연령, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다. 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다. 본 발명의 제조 방법에 따라 제조된 추출물 또는 화합물을 포함하는 조성물의 투여방법은 경구투여 또는 정맥투여가 바람직하고, 일반적으로 그 유효 용량은 경구투여인 경우에는 보통 성인을 기준으로 1회에 1 내지 500 ㎎/㎏이 바람직하며, 정맥투여인 경우에는 1 내지 100 ㎎/㎏이 바람직하며, 하루 2-3 회 투여될 수 있다. 특정 환자에 대한 투여용량 수준은 성별, 연령, 유향상태, 식이, 투여시간, 투여방법, 약제혼합, 환자의 상태 및 신경 질환의 발병 정도에 따라 변화될 수 있다.
The composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the sex of the patient, age, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. May be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art. The method for administration of the composition comprising the extract or the compound prepared according to the preparation method of the present invention is preferably oral or intravenous. Generally, the effective dose is usually 1 to 10 times, 500 mg / kg is preferable, and in case of intravenous administration, 1 to 100 mg / kg is preferable, and it can be administered 2-3 times a day. The dosage level for a particular patient may vary depending on the sex, age, body condition, diet, time of administration, administration method, drug mix, patient condition, and severity of neurological disease.
또한, 본 발명은 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 유향(Olibanum) 에탄올 추출물을 유효성분으로 함유하는 췌장암 예방용 기능성 식품을 제공한다.In addition, the present invention provides a functional food for the prevention of pancreatic cancer, which contains as an active ingredient an olibanum ethanol extract containing a food-acceptable food-aid additive.
본 발명의 기능성 식품은 에탄올 추출물을 총중량에 대해 0.1 내지 5중량% 포함하는 것이 바람직하며, 1중량%로 포함하는 것이 더욱 바람직하다. 본 발명의 기능성 식품은 그 제형에 있어서 특별히 한정되는 바는 없으며, 예를 들어 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 유향식품을 모두 포함한다.The functional food of the present invention preferably contains 0.1 to 5% by weight, more preferably 1% by weight, of the ethanol extract in the total weight. The functional food of the present invention is not particularly limited in its formulation and can be used in various food products such as dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramie noodle, Various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, all of which include oriental foods in a conventional sense.
본 발명에 있어서 "기능성 식품"은 유향기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.
In the present invention, the term "functional food" means food prepared and processed by using raw materials or ingredients having functionality useful to the human body according to Law No. 6727 on frankincense functional foods, and " And function of the nutrient for the purpose of obtaining a beneficial effect in health use such as controlling the nutrient or physiological action.
본 발명에서는 Panc-1 췌장암 세포에 본 발명의 유향 추출물을 투입한 결과, Panc-1 췌장암 세포가 사멸하는 것을 확인하였다(도 1 참조). 따라서, 유향 추출물이 췌장암 치료 효과가 있다는 것을 새롭게 알 수 있다. 이에, 본 발명에서는 유향 추출물을 유효성분으로 함유하는 췌장암 예방용 기능성 식품을 제조함으로써 본 발명을 완성하였다(제조예 2 참조)
In the present invention, the oriental extract of the present invention was injected into Panc-1 pancreatic cancer cells, and it was confirmed that Panc-1 pancreatic cancer cells died (see FIG. 1 ). Therefore, it is newly found that oriental extract is effective for the treatment of pancreatic cancer. In the present invention, the present invention has been completed by preparing a functional food for the prevention of pancreatic cancer containing an oriental extract as an active ingredient (see Production Example 2 )
상기에서 살펴본 바와 같이, 본 발명의 유향 추출물은 췌장암 세포의 성장을 억제하고 세포사멸을 유도한다. 따라서 본 발명에 따른 췌장암 치료용 조성물은 췌장암 환자의 치료에 매우 효과적일 것이다.
As described above, the oriental extract of the present invention inhibits the growth of pancreatic cancer cells and induces apoptosis. Therefore, the composition for treating pancreatic cancer according to the present invention will be very effective for the treatment of pancreatic cancer patients.
도 1은 인간 췌장암 세포인 Panc-1 세포에서 유향의 도입이 췌장암 세포의 성장에 미치는 영향을 알아보기 위한 Alamar Blue 분석 결과이고, 이때 X축은 유향 추출물의 농도이고, Y축은 생존한 인간 췌장암 세포의 생존율을 나타낸다. FIG. 1 shows the results of Alamar Blue analysis to examine the effect of frankincense on the growth of pancreatic cancer cells in human pancreatic cancer cell, Panc-1 cells, wherein the X axis is the concentration of oriental extract and the Y axis is the survival of human pancreatic cancer cells Survival rate.
이하, 본 발명을 하기 실시예에 의거하여 보다 상세하게 설명하고자 한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명은 하기 실시예에 의해 한정되는 것이 아니고, 본 발명의 기술적 사상을 벗어나지 않는 범위 내에서 치환 및 균등한 타 실시예로 변경할 수 있음은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 있어서 명백할 것이다.
Hereinafter, the present invention will be described in more detail based on the following examples. It should be noted, however, that the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The present invention is not limited to the following examples. Will be apparent to those skilled in the art to which the present invention pertains.
<실시예 1> 유향 추출물의 제조≪ Example 1 > Preparation of oriental extract
서울 약재상에서 구입한 유향(중국산) 3 ㎏을 실온에서 5일간 건조하고 분쇄하였다. 상기 분쇄된 유향을 95% 에탄올(ethanol) 30 ℓ에 침지시키고 50℃에서 24시간 동안 추출하였다. 이것을 여과지를 통하여 여과한 후 45℃ 감압 조건에서 건조 및 농축하여 총 추출물 296 g을 수득하고, -20℃에서 보관하였다.
3 ㎏ of frankincense (Chinese) purchased from Seoul Medicinal Plant was dried and pulverized at room temperature for 5 days. The ground flour was immersed in 30 L of 95% ethanol and extracted at 50 DEG C for 24 hours. This was filtered through a filter paper, dried and concentrated under reduced pressure at 45 ° C to obtain 296 g of a total extract, which was stored at -20 ° C.
<실시예 2> 유향 추출물이 췌장암 세포의 성장에 미치는 영향<Example 2> Effect of oriental extract on growth of pancreatic cancer cells
상기 실시예 1에서 추출한 유향 추출물이 췌장암 세포의 성장에 미치는 영향을 알아보기 위하여, 인간 췌장암 세포인 Panc-1 세포에 유향의 에탄올 추출물을 48시간 처리하고 Alamar Blue 분석을 시행하였다. Alamar Blue 분석은 MTT 분석의 변형된 형태인데, 특정 효소에 의해서 분해되는 화합물을 살아있는 세포에 처리한 후 화합물이 분해되면서 나오는 생성물의 형광 세기를 측정함으로써 약물을 처리한 후 살아있는 세포의 상대적인 숫자를 알아내는 실험방법이다. 하기에서 보다 상세히 설명한다.
In order to examine the effect of the extract of Oriental japonica extract obtained from Example 1 on the growth of pancreatic cancer cells, Panc-1 cells, which are human pancreatic cancer cells, were subjected to Alamar Blue analysis for 48 hours after treatment with oriental ethanol extract. The Alamar Blue assay is a modified form of MTT assay that measures the fluorescence intensity of a product after degradation of a compound that is degraded by a specific enzyme into a living cell to determine the relative number of living cells after treatment It is an experimental method. This will be described in more detail below.
<2-1> 인간 췌장암 세포주의 준비 및 처리<2-1> Preparation and treatment of human pancreatic cancer cell line
본 발명에 사용된 췌장암 세포주인 Panc-1 세포는 한국세포주은행(Korean Cell Line Bank, KCLB)으로부터 분양받아 실험에 이용하였다. 구체적으로, Panc-1췌장암 세포를 10% FBS(fetal bovine serum, 소태아혈청)(Welgene)와 25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)를 포함하는 DMEM(Dulbeco's Modified Eagle's Medium) 배지에서 계대배양하였다.
Panc-1 cells, the pancreatic cancer cell line used in the present invention, were purchased from Korean Cell Line Bank (KCLB) and used for the experiment. Specifically, Panc-1 pancreatic cancer cells were cultured in Dulbeco's Modified Eagle's (DMEM) medium supplemented with 10% fetal bovine serum (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) Medium) medium.
<2-2> Panc-1 췌장암 세포의 세포 성장 억제 측정<2-2> Inhibition of Cell Growth of Panc-1 Pancreatic Cancer Cells
상기 실시예 1에서 추출한 유향 추출물이 췌장암 세포인 Panc-1 세포에 대하여 성장을 억제시키는 효과를 확인하였다. 구체적으로, 96 웰 플레이트에 각 웰 당 4.5 X 103 개의 Panc-1 췌장암 세포를 주입(seeding)하고 24시간 동안 배양한 후, DMSO(Dimethyl sulfoxide)에 녹인 상기 유향 에탄올 추출물을 각각 0 내지 100 ㎍/㎖ 농도(구체적으로, 각각 0, 3.125, 6.25, 12.5, 25, 50 및 100 ㎍/㎖ 농도)로 48시간 동안 처리하였을 때, 세포 성장을 저해하는 정도를 확인하였다(표 1). 각 농도의 추출물을 처리한 후, 96-웰 플레이트에서 각 웰에 채워진 0.2 ㎖의 세포 배양액에 20 ㎕의 Alamar Blue 시약을 첨가한 후 플레이트를 인큐베이터에서 2시간 동안 배양하였다. 각 웰의 세포를 고르게 반응시키기 위하여 플레이트를 천천히 흔들고, 544 ㎚의 파장에서 조사광을 조사하면서 590 ㎚에서 형광의 세기를 형광광도계(Fluorescence Microplate Reader; Molecular Devices Corp.)로 측정하였고, 췌장암 세포의 생존율을 도 1에 나타내었다.
The effect of the fragrance extract of Example 1 on growth of Panc-1 cells, which are pancreatic cancer cells, was confirmed. Specifically, 4.5 X 10 3 Panc-1 pancreatic cancer cells were seeded on a 96-well plate and cultured for 24 hours. Then, the cells were cultured in DMSO (dimethyl sulfoxide) Ethanol extract was treated for 48 hours at a concentration of 0 to 100 μg / ml (specifically, 0, 3.125, 6.25, 12.5, 25, 50 and 100 μg / ml, respectively) (Table 1). After treating each concentration of the extract, 20 μl of Alamar Blue reagent was added to 0.2 ml of the cell culture solution filled in each well in a 96-well plate, and the plate was cultured in an incubator for 2 hours. The plate was gently shaken to react cells in each well, and the intensity of fluorescence was measured at 590 nm using a fluorescence photometer (Molecular Devices Corp.) while irradiating light at a wavelength of 544 nm. Survival rate is shown in Fig.
그 결과, 표 1 및 도 1에서 나타난 바와 같이, 유향의 처리 농도가 높을수록 췌장암 세포의 성장이 감소하였으며, 이로부터 유향이 췌장암 치료 효과를 가짐을 알 수 있었다. 즉, 25 ㎍/㎖에서 25.8%, 50 ㎍/㎖에서 74.0%, 100 ㎍/㎖에서 96.3%로 췌장암 세포를 사멸시켰다. 아울러, EC50(half maximal inhibitory concentration)은 36.1 ㎍/㎖로 측정되었다. 상기 표 1에서 유향을 처리하지 않은 대조군의 췌장암 세포의 생존율 수를 1을 기준으로 하여 각각의 유향 처리 농도에 따른 48시간 후의 췌장암 세포의 상대적 세포수를 기재하였다. 이와 같이, 본 발명의 유향 추출물은 우수한 Panc-1 췌장암 세포 사멸 활성을 가지며, 나아가 췌장암 치료 및 예방 활성을 가진다는 것을 입증한다.
As a result, as shown in Table 1 and FIG. 1, as the concentration of oriental treatment increased, the growth of pancreatic cancer cells decreased, indicating that oriental pancreatic cancer treatment was effective. That is, pancreatic cancer cells were killed by 25.8% at 25 ㎍ / ㎖, 74.0% at 50 ㎍ / ㎖ and 96.3% at 100 ㎍ / ㎖. In addition, the EC 50 (half maximal inhibitory concentration) was measured as 36.1 / / ml. Table 1 shows the relative number of cells of pancreatic cancer cells after 48 hours according to the concentration of each treatment, based on the number of survival rates of the control group of pancreatic cancer cells not treated with scent 1 on the basis of 1. Thus, the fragrance extract of the present invention has excellent Panc-1 pancreatic cancer cell killing activity and further demonstrates that it has pancreatic cancer treatment and prevention activity.
<실시예 3> 유향 추출물에 의한 급성독성 시험≪ Example 3 > Acute toxicity test with oriental extract
본 발명에 이용된 유향은 널리 약재로 이용되고 있어서 안정성에 문제가 없을 것으로 판단하였으나, 경구 투여시 및 복강내 투여시의 독성 실험을 수행하여 이를 확인하고자 하였다.Although the fragrance used in the present invention was widely used as a medicament, it was judged that there would be no problem in stability, but the toxicity test at the time of oral administration and intraperitoneal administration was performed to confirm this.
6주령의 특정병원부재(SPF) SD계 랫트를 사용하여 급성독성실험을 실시하였다. 군당 2 마리씩의 동물에 본 발명의 실시예 1의 유향 추출물을 각각 0.5% 메틸셀룰로즈 용액에 현탁하여 5 g/㎏의 용량으로 단회 경구투여하였다. 시험물질 투여후 동물의 폐사여부, 임상증상, 체중변화를 관찰하고 혈액학적 검사와 혈액생화학적검사를 실시하였으며, 부검하여 육안으로 복강장기와 흉강장기의 이상여부를 관찰하였다.Acute toxicity tests were carried out using 6-week-old SPF SD rats. The oriental extract of Example 1 of the present invention was suspended in a 0.5% methylcellulose solution and administered to a 2-group animal in a single dose at a dose of 5 g / kg. After the administration of the test substance, the mortality, clinical symptoms, and weight changes of the animals were observed, and hematological tests and blood biochemical tests were carried out, and autopsy was performed to observe the abnormalities of the abdominal organs and thoracic organs.
시험결과, 시험물질을 투여한 모든 동물에서 특기할 만한 임상증상이나 폐사된 동물은 없었으며, 체중변화, 혈액검사, 혈액생화학 검사, 부검소견 등에서도 독성변화는 관찰되지 않았다. 이상의 결과 유향 추출물은 모두 랫트에서 5 g/㎏까지 독성변화를 나타내지 않으며 경구 투여 최소치사량 (LD50)은 5 g/㎏이상인 안전한 물질로 판단되었다.
As a result of the test, there were no clinically symptomatic or dead animals in all the animals to which the test substance was administered, and no toxic change was observed in weight change, blood test, blood biochemical test, and autopsy findings. As a result, the extracts of Oriental japonica did not show any toxic change up to 5 g / kg in rats and the minimum oral dose (LD 50 ) was 5 g / kg or more.
<제조예 1> 유향 추출물을 유효성분으로 함유하는 췌장암 치료제의 제조<Preparation Example 1> Preparation of therapeutic agent for pancreatic cancer containing oriental extract as an active ingredient
본 발명자들은 상기 실시예를 통해 유향 추출물의 췌장암 치료 효능이 뛰어남을 확인하여 유향 추출물을 유효성분으로 함유하는 췌장암 치료제를 하기와 같이 제조하였다. 또한, 하기 치료제의 제조예는 치료제 뿐만 아니라 유향 식품의 제조에도 응용하여 사용될 수 있다.
The inventors of the present invention confirmed that pancreatic cancer treatment efficacy of oriental extract was excellent in the above Examples, and thus a pancreatic cancer treatment agent containing oriental extract as an active ingredient was prepared as follows. The preparation examples of the following therapeutic agents can be applied not only to therapeutic agents but also to the production of oriental foods.
<1-1> 유향 추출물을 함유하는 연질캅셀(soft gelatin capsules)<1-1> Soft gelatin capsules containing oriental extracts
유향 추출물 20%
비타민 C 4.5%Vitamin C 4.5%
비타민 D3 0.001%Vitamin D 3 0.001%
황산망간 0.1%Manganese sulfate 0.1%
밀납 10%Wax 10%
팜유 25%Palm oil 25%
홍화씨유 30.399%
Safflower oil 30.399%
<1-2> 유향 추출물을 함유하는 정맥주사용 제제의 제조 <1-2> Preparation of an intravenous formulation containing oriental extract
유향 추출물 0.2%Yucca extract 0.2%
만니톨 0.3%Mannitol 0.3%
생리식염수 9.5%
Physiological saline 9.5%
<1-3> 유향 추출물을 함유하는 정제(tablet)≪ 1-3 > Tablets containing oriental extracts
유향 추출물 35%Oriental extract 35%
비타민 C 10%Vitamin C 10%
비타민 D3 0.001%Vitamin D 3 0.001%
황산망간 0.1%Manganese sulfate 0.1%
결정셀룰로오즈 25.0%Crystalline cellulose 25.0%
유당 17.999%Lactose 17.999%
스테아린산마그네슘 2%
Magnesium stearate 2%
<제조예 2> 유향 추출물을 유효성분으로 함유하는 기능성 식품의 제조≪ Preparation Example 2 > Preparation of functional food containing oriental extract as an active ingredient
본 발명자들은 상기 실시예를 통해 유향 추출물이 췌장암 치료 활성이 뛰어남을 확인하여 이를 유효성분으로 함유하는 기능성 식품을 하기와 같이 제조하였다.
The inventors of the present invention confirmed through the above Examples that the extract of Oriental japonica was excellent in the treatment of pancreatic cancer and prepared a functional food containing the active ingredient as follows.
<2-1> 음료의 제조<2-1> Production of beverage
꿀 522 ㎎Honey 522 mg
치옥토산아미드 5 ㎎5 mg < RTI ID = 0.0 >
니코틴산아미드 10 ㎎Nicotinic acid amide 10 mg
염산리보플라빈나트륨 3 ㎎3 mg of sodium riboflavin hydrochloride
염산피리독신 2 ㎎Pyridoxine hydrochloride 2 mg
이노시톨 30 ㎎Inositol 30 mg
오르트산 50 ㎎Orthoic acid 50 mg
유향 추출물 0.48 ~ 1.28 ㎎Oriental extracts 0.48 to 1.28 mg
물 200 ㎖200 ml of water
상기 조성 및 함량으로 하여 통상적인 방법을 사용하여 음료를 제조하였다.
A beverage was prepared using the above-mentioned composition and content by a conventional method.
<2-2> 츄잉껌의 제조<2-2> Production of chewing gum
껌베이스 20 %
설탕 76.36 ~ 76.76 %Sugar 76.36 ~ 76.76%
유향 추출물 0.24 ~ 0.64 %Oriental extract 0.24 ~ 0.64%
후르츠향 1 %Fruit flavor 1%
물 2 %Water 2%
상기 조성 및 함량으로 하여 통상적인 방법을 사용하여 츄잉껌을 제조하였다.
Chewing gum was prepared using the above-mentioned composition and content by a conventional method.
<2-3> 캔디의 제조<2-3> Manufacture of candy
설탕 50 ~ 60 %Sugar 50 to 60%
물엿 39.26 ~ 49.66 %Syrup 39.26 ~ 49.66%
유향 추출물 0.24 ~ 0.64 %Oriental extract 0.24 ~ 0.64%
오렌지향 0.1 %Orange fragrance 0.1%
상기 조성 및 함량으로 하여 통상적인 방법을 사용하여 캔디를 제조하였다.
The composition and the content of the candy were prepared using a conventional method.
<2-4> 비스켓의 제조<2-4> Production of biscuit
박력1급 88 ㎏First class 88 ㎏ power
중력1급 76.4 ㎏Gravity Class 1 76.4 kg
정백당 16.5 ㎏16.5 kg
식염 2.5 ㎏Salt 2.5 ㎏
포도당 2.7 ㎏Glucose 2.7 kg
팜쇼트닝 40.5 ㎏Palm shortening 40.5 kg
암모 5.3 ㎏Ammonium 5.3 kg
중조 0.6 ㎏0.6 kg
중아황산나트륨 0.55 ㎏Sodium bisulfite 0.55 kg
쌀가루 5.0 ㎏Rice powder 5.0 kg
비타민 B1 0.003 ㎏Vitamin B1 0.003 kg
비타민 B2 0.003 ㎏Vitamin B2 0.003 kg
밀크향 0.16 ㎏Milk flavor 0.16 kg
물 71.1 ㎏Water 71.1 kg
전지분유 4 ㎏Whole milk powder 4 ㎏
대용분유 1 ㎏1 kg of substitute milk powder
제일인산칼슘 0.1 ㎏Calcium phosphate 0.1 kg
살포염 1 ㎏Spray salt 1 kg
분무유 25 ㎏Spray oil 25 kg
유향 추출물 0.2 ~ 0.5 ㎏Oriental extract 0.2 ~ 0.5 ㎏
상기 조성 및 함량으로 하여 통상적인 방법을 사용하여 비스켓을 제조하였다.
The biscuits were prepared using the above-mentioned composition and content by a conventional method.
<2-5> 아이스크림의 제조<2-5> Production of ice cream
유지방 10.0 %Fat milk 10.0%
무지유고형분 10.8 %Solid oil content 10.8%
설탕 12.0 %Sugar 12.0%
물엿 3.0 %Starch syrup 3.0%
유화안정제(스팬, span) 0.5 %Emulsion stabilizer (span) 0.5%
향료(스트로베리) 0.15 %Perfume (Strawberry) 0.15%
물 63.31 ~ 62.91 %Water 63.31 ~ 62.91%
유향 추출물 0.24 ~ 0.64 %Oriental extract 0.24 ~ 0.64%
상기 조성 및 함량으로 하여 통상적인 방법을 사용하여 아이스크림을 제조하였다.
Ice cream was prepared using the above-mentioned composition and content by a conventional method.
<2-6> 쵸코렛의 제조<2-6> Manufacture of Chocolate
설탕 34.36 ~ 34.76 %Sugar 34.36 ~ 34.76%
코코아 버터 34 %Cocoa Butter 34%
코코아 매스 15 %Cocoa mass 15%
코코아 파우다 15 %Cocoa powder 15%
레시틴 0.5 %Lecithin 0.5%
바닐라향 0.5 %Vanilla flavor 0.5%
유향 추출물 0.24 ~ 0.64 %Oriental extract 0.24 ~ 0.64%
상기 조성 및 함량으로 하여 통상적인 방법을 사용하여 초코렛을 제조하였다.
The composition and the content thereof were used to prepare chocolate by a conventional method.
한편, 본 발명의 구체적 범위는 상기 기술한 실시예 보다는 특허청구범위에 의하여 한정지어지며, 특허청구 범위의 의미와 범위 및 그 등가적 개념으로 도출되는 모든 변경 및 변형된 형태를 본 발명의 범위로 포함하여 해석하여야 한다.It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention, and are not intended to limit the scope of the invention. .
Claims (7)
A composition for prevention and treatment of pancreatic cancer comprising an ethanol extract of Olibanum .
The composition for preventing and treating pancreatic cancer according to claim 1, wherein the ethanol extract is extracted at 50 캜 for 24 hours and dried and concentrated under reduced pressure at 45 캜.
The composition for preventing and treating pancreatic cancer according to claim 1, wherein the composition comprises a pharmaceutically acceptable carrier or diluent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110040577A KR101752487B1 (en) | 2011-04-29 | 2011-04-29 | Composition for Treatment of Pancreatic Cancer and Functional Food Comprising Extract of Olibanum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110040577A KR101752487B1 (en) | 2011-04-29 | 2011-04-29 | Composition for Treatment of Pancreatic Cancer and Functional Food Comprising Extract of Olibanum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120122443A KR20120122443A (en) | 2012-11-07 |
| KR101752487B1 true KR101752487B1 (en) | 2017-07-03 |
Family
ID=47508704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110040577A KR101752487B1 (en) | 2011-04-29 | 2011-04-29 | Composition for Treatment of Pancreatic Cancer and Functional Food Comprising Extract of Olibanum |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101752487B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101670071A (en) | 2009-09-25 | 2010-03-17 | 卢速江 | Traditional Chinese medicine preparation for treating cancer and preparation method thereof |
-
2011
- 2011-04-29 KR KR1020110040577A patent/KR101752487B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101670071A (en) | 2009-09-25 | 2010-03-17 | 卢速江 | Traditional Chinese medicine preparation for treating cancer and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120122443A (en) | 2012-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20120109141A (en) | Composition for treatment of lung cancer and functional food comprising extract of gleditsiae semen | |
| KR20130022394A (en) | Composition for treatment of pancreatic cancer and functional food comprising extract of caryophylli cortex | |
| KR101776793B1 (en) | Composition for Treatment of Lung Cancer and Functional Food Comprising Extract of Olibanum | |
| KR20120111125A (en) | Composition for treatment of renal cell carcinoma and functional food comprising extract of cannabis semen | |
| KR101752487B1 (en) | Composition for Treatment of Pancreatic Cancer and Functional Food Comprising Extract of Olibanum | |
| KR101752486B1 (en) | Composition for Treatment of Pancreatic Cancer and Beauty Expenses Composition Comprising Extract of Pharbitis Semen | |
| KR101794145B1 (en) | Composition for Treatment of Pancreatic Cancer and Beauty Expenses Composition Comprising Extract of Benzoinum | |
| KR20120122437A (en) | Composition for Treatment of Pancreatic Cancer and Functional Food Comprising Extract of Inulae Flos | |
| KR102054437B1 (en) | Composition for Treatment of Renal Cell and Functional Food Comprising Extract of Gleditsiae Semen | |
| KR101865377B1 (en) | Composition for Treatment of Brain Cancers and Functional Food Comprising Extract of Alpiniae Semen | |
| KR20120109139A (en) | Composition for treatment of lung cancer and functional food comprising extract of melandrii herba | |
| KR20120122410A (en) | Composition for Treatment of Renal Cell Carcinoma and Functional Food Comprising Extract of Saussureae Radix | |
| KR101814132B1 (en) | Composition for Treatment of Lung Cancer and Functional Food Comprising Extract of Patriniae Radix | |
| KR101794135B1 (en) | Composition for Treatment of Renal Cell Carcinoma and Functional Food Comprising Extract of Galla Rhois | |
| KR101752485B1 (en) | Composition for Treatment of Renal Cell Carcinoma and Functional Food Comprising Extract of Olibanum | |
| KR101794142B1 (en) | Composition for Treatment of Pancreatic Cancer and Beauty Expenses Composition Comprising Extract of Ulmi Pasta Semen | |
| KR102054451B1 (en) | Composition for Treatment of Pancreatic Cancer and Functional Food Comprising Extract of Gleditsiae Semen | |
| KR20120111123A (en) | Composition for treatment of pancreatic cancer and functional food comprising extract of circii radix | |
| KR20120122429A (en) | Composition for Treatment of Pancreatic Cancer and Functional Food Comprising Extract of Mori Radicis Cortex | |
| KR20180037930A (en) | Composition for Treatment of Pancreatic CancerComprising Extract of Myristicae Semen | |
| KR20120111126A (en) | Composition for treatment of pancreatic cancer and functional food comprising extract of cannabis semen | |
| KR101789323B1 (en) | Composition for Treatment of Renal Cell Carcinoma and Functional Food Comprising Extract of Torilidis Fructus | |
| KR101790742B1 (en) | Composition for Treatment of Renal Cell Carcinoma and Functional Food Comprising Extract of Bupleuri Radix | |
| KR101790749B1 (en) | Composition for Treatment of Pancreatic Cancer and Beauty Expenses Composition Comprising Extract of Araliae Cordatae Radix | |
| KR20120122427A (en) | Composition for Treatment of Pancreatic Cancer and Functional Food Comprising Extract of Hedyotidis Diffusae Herba |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |